Mechanisms of Resistance to Oncogenic KRAS Inhibition in Pancreatic CancerJulien Dilly, Andrew J. Aguirre, Brian M. Wolpin et al.|Cancer Discovery|2024Cited by 234
Tumour-selective activity of RAS-GTP inhibition in pancreatic cancerUrszula N. Wasko, Miroslav Sekulic, Jingjing Jiang et al.|Nature|2024Cited by 175
A neomorphic protein interface catalyzes covalent inhibition of RAS <sup>G12D</sup> aspartic acid in tumorsCaroline E. Weller, David Wildes, G. Leslie Burnett et al.|Science|2025Cited by 31
Author Correction: Tumour-selective activity of RAS-GTP inhibition in pancreatic cancerUrszula N. Wasko, Miroslav Sekulic, Jingjing Jiang et al.|Nature|2024Cited by 5
Abstract 2930: Intrinsic payload resistance governs responses to datopotamab deruxtecan, a TROP2 antibody drug conjugate, in pancreatic cancer model systemsPanot Sainamthip, Harshabad Singh, Kazuki Takahashi et al.|Cancer Research|2025Cited by 1